Your cart is currently empty!
Category: Kidney Cancer
Vincristine Sulphate
Description
This page contains brief details about the drug vincristine sulphate, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Vincristine sulphate is a chemotherapy medication containing the active constituent vincristine sulphate. It belongs to a class of drugs called vinca alkaloids, which inhibit the growth of cancer cells. This medication treats blood, head, breast, neck, kidney, bone, or lung cancers. It treats rhabdomyosarcoma (cancer that affects muscle tissue) and neuroblastoma (cancer that develops from immature nerve cells). It may also treat multiple myeloma (cancer of plasma cells), thyroid cancer, and a blood disorder known as idiopathic thrombocytopenic purpura (ITP). Cancer is a disorder in which cells multiply uncontrolled and abnormally.
Vincristine sulphate was first approved by the FDA in 1963 for treating acute lymphocytic leukemia (ALL). Since then, it has received additional approvals for treating other types of cancer. Like all chemotherapy drugs, it can cause side effects, such as nausea, vomiting, constipation, hair loss, and fatigue. Patients should discuss the potential benefits and risks of treatment with their doctor.
Mechanism of Action of Vincristine Sulphate
The therapeutic effect of vincristine sulphate inhibits the growth and spread of cancer cells. Vincristine sulphate disrupts the formation and function of microtubules, which are structures inside cells that help with cell division and movement. By interfering with microtubule function, this medication can prevent cancer cells from dividing and multiplying and can also cause them to die.
Uses of Vincristine Sulphate
Vincristine sulphate is used to treat various types of cancer, including blood cancers such as acute lymphocytic leukemia (ALL), head and neck cancers, breast cancer, kidney cancer, bone cancer, and lung cancer. It is also used to treat idiopathic thrombocytopenic purpura (a condition in which the immune system attacks and destroys platelets cells) and multiple myeloma (a type of blood cancer that affects plasma cells). In addition, this medication is used to treat rhabdomyosarcoma (cancer that forms in the body’s soft tissues) and neuroblastoma (cancer that develops in certain nerve cells). It may also be used to treat thyroid cancer.
Vincristine Sulphate Dosage available
A healthcare professional usually administers vincristine sulphate intravenous injection (IV) in a hospital or clinical setting. It should not be taken orally or applied topically to the skin. If you miss a dose, do not double the dose to make up for the missed one.
Lenvatinib
Description
This page contains brief details about the drug lenvatinib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Lenvatinib is composed of the active ingredient Lenvatinib. It is a tyrosine kinase inhibitor indicated for progressive or advanced thyroid cancer when radioactive iodine therapy is not beneficial. It is also used to treat previously untreated liver cancer patients who are not eligible for surgical treatment. Patients who have had an allergic reaction to lenvatinib or any of its components should not take this medication. Patients should inform their dentist or oral surgeon that they are taking this medication, as it can impair wound healing and increase the risk of bleeding.
Lenvatinib was first approved by the United States Food and Drug Administration (FDA) in February 2015 for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. Since then, it has received additional approvals for other indications, including the treatment of hepatocellular carcinoma (liver cancer) and renal cell carcinoma (kidney cancer).
Mechanism of Action of Lenvatinib
Lenvatinib blocks the enzyme receptor tyrosine kinases (RTKs). RTKs develop new blood vessels that supply oxygen and nutrients to the cells and help them grow. This medicine inhibits the receptors that facilitate the growth of blood vessels in tumor cells. RTKs are present in high concentrations in cancer cells, and administration of this medicine slows down the rate of cancer cells’ growth and multiplication.
Uses of Lenvatinib
Lenvatinib is a medication that is used to treat several types of cancer, including thyroid, liver, and kidney cancer. In patients with radioactive iodine-refractory differentiated thyroid cancer, it can be used to slow the progression of the disease and reduce tumor size. It is also approved for the treatment of unresectable hepatocellular carcinoma (HCC), which is the most common type of liver cancer.
Lenvatinib Dosage available
Lenvatinib is an oral medication that is usually taken once a day, at approximately the same time each day, with or without food. It should be taken as prescribed by a doctor or other healthcare provider. These capsules should be swallowed whole with a glass of water. They should not be crushed, chewed, or opened, as this can affect the way the medication is absorbed and decrease its effectiveness. You should not take a double dose to make up the second dose.
Cyclosporine
Description
This page contains brief details about the drug cyclosporine, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Cyclosporine is an immunosuppressant which was approved for its medical use on 1983.
Mechanism of Action of Cyclosporine
Cyclosporine is an immunosuppressant which prevents organ rejection in organ transplantation. It is classified as an immunosuppressant belonging to the category of Calcineurin inhibitors. Cyclosporine works inhibiting cytochrome P450 3A4, P-glycoprotein and interleukins to suppress the cell mediated immune response. Cyclosporine is often prescribed along with other immunosuppressants like azathioprine and mycophenolate mofetil.
Uses of Cyclosporine
Cyclosporine has been developed to prevent organ rejection in adult and pediatric patients receiving an allogeneic transplant of the liver, kidney, heart, or lung. it is indicated for It is also prescribed to treat rheumatoid arthritis for patients who have not responded adequately to methotrexate.
Cyclosporine Dosage available
Cyclosporine is available in the form of capsule, injection and oral solution. Cyclosporine Capsule is available in the doses 25mg, 50mg and 100mg. Your healthcare provider will administer Cyclosporine 50mg Injection if you are unable to tolerate oral capsule or suspension. Your healthcare provider will prescribe the accurate dose based on the organ transplanted, body weight and health condition.
Tacrolimus
Description
This page contains brief details about the drug tacrolimus, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Tacrolimus is an immunosuppressant that was approved for its medical use on 8th April 1994.
Mechanism of Action of Tacrolimus
Tacrolimus is an immunosuppressant that prevents organ rejection in organ transplantation. It is classified as an immunosuppressant belonging to the category of Calcineurin inhibitors. Tacrolimus works by binding to a protein called FKBP-12 and forms a complex called tacrolimus-FKBP, which inhibits the action of calcineurin phosphatase. This, in turn, inhibits the formation of T cells and suppresses the immune response. Tacrolimus is often prescribed along with other immunosuppressants like azathioprine and mycophenolate mofetil.
Uses of Tacrolimus
Tacrolimus has been developed to prevent organ rejection in adult and pediatric patients receiving an allogeneic transplant of the liver, kidney, heart, or lung.
Tacrolimus Dosage available Tacrolimus is available in the form of capsules, injections, oral suspensions, and ointments. Tacrolimus Capsule is available in doses 0.5mg, 1mg, and 5mg. your healthcare provider will administer Tacrolimus Injection (5mg/ml) if you are unable to tolerate an oral capsule or suspension. Your healthcare provider will prescribe the accurate dose based on the organ transplanted, body weight, and health condition. Patients diagnosed with cystic fibrosis might require higher doses.
Sorafenib Tosylate
Oncology